36960-03-9Relevant articles and documents
Regioselective Wacker-Type Oxidation of Internal Olefins in tBuOH Using Oxygen as the Sole Oxidant and tBuONO as the Organic Redox Cocatalyst
Huang, Qing,Li, Ya-Wei,Ning, Xiao-Shan,Jiang, Guo-Qing,Zhang, Xiao-Wei,Qu, Jian-Ping,Kang, Yan-Biao
, p. 965 - 969 (2020/02/15)
A regioselective Wacker-Tsuji oxidation of internal olefins in tBuOH has been developed using oxygen as the terminal oxidant and tert-butyl nitrite as the simple organic redox cocatalyst without the involvement of hazardous cocatalysts or harsh reaction conditions. A series of internal olefins bearing various functional groups can be oxidized to the corresponding substituted ketones in generally good yields with high regioselectivities.
Synthesizing method of alpha-arone or alpha-hetero-arone
-
, (2018/09/08)
The invention discloses a synthesizing method of alpha-arone or alpha-hetero-arone and belongs to the technical field of metal organic catalyzing. The synthesizing method has the advantages that a terminal alkynyl compound, oxynitride and a proton supply agent is catalyzed by univalence metal salt to obtain N-O pyridine oxynitride enol salt, purification and separation are not needed, and the N-Opyridine oxynitride enol salt is allowed to have reaction with arene and hetero-arene in a one-pot manner to obtain the alpha-arone or alpha-hetero-arone; the method is high in functional group tolerance, wide in substrate application range, high in yield, simple and easy to operate and easy in final product separation and purification.
Methods and Compositions for Treatment of Scleritis and Related Disorders
-
Page/Page column 29-32, (2008/12/05)
The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W1, W2, R1, L, X, Y, Z, and n1 are defined as described herein.